Compugen - CGEN Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings or view top-rated stocks.

5 brokers have issued 1 year price targets for Compugen's stock. Their CGEN share price forecasts range from $2.00 to $12.00. On average, they predict the company's share price to reach $6.20 in the next year. This suggests a possible upside of 723.4% from the stock's current price.
View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts.

Compugen's stock was trading at $4.30 at the beginning of the year. Since then, CGEN stock has decreased by 82.5% and is now trading at $0.7530.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CGEN earnings forecast.

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. During the same period in the prior year, the company posted ($0.11) earnings per share.

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (15.76%), Nikko Asset Management Americas Inc. (0.00%), Sumitomo Mitsui Trust Holdings Inc. (0.00%), Renaissance Technologies LLC (1.90%), Artisan Partners Limited Partnership (0.00%) and Antonetti Capital Management LLC (0.76%).

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CGEN stock can currently be purchased for approximately $0.75.

Compugen (NASDAQ:CGEN) has a market capitalization of $65.23 million and generates $6 million in revenue each year. The biotechnology company earns $-34,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The official website for the company is www.cgen.com. The biotechnology company can be reached via phone at (723) 765-8585, via email at ir@cgen.com, or via fax at 972-3765-8555.